Experimental drug SHR-A1904 takes on rare cancer
NCT ID NCT07520357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests an experimental drug called SHR-A1904 in 23 people with advanced neuroendocrine carcinoma whose cancer has worsened after standard chemotherapy. The study measures how many patients have their tumors shrink or disappear, how long they live without the cancer growing, and overall survival. It is a single-center, prospective study that will also track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1904 (an experimental drug given by injection)
What this could lead to
If successful, this could provide a new treatment option for people with advanced neuroendocrine carcinoma who have not responded to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drug may cause side effects and might not shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact